Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Abstract

Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib. PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.